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France; and 7Division of Nephrology, Ambroise Paré University Hospital, APHP, Boulogne-Billancourt, FranceIntroduction: Chronic kidney disease (CKD) is often associated with poor hypertension control and
treatment resistance, but whether CKD modiﬁes the effect of hypertension control on outcomes is
unknown.
Methods: We studied 10-year mortality and cardiovascular events according to hypertension control
status and CKD (glomerular ﬁltration rate <60 ml/min/1.73m2) in 4262 community-dwelling individuals
(40% men) more than 65 years of age.
Results: At baseline, 19% had CKD, and 31.2% had controlled hypertension on #3 antihypertensive drugs,
62.3% uncontrolled hypertension $140/90 mm Hg on #2 drugs, and 6.5% apparent treatment-resistant
hypertension (aTRH) $140/90 mm Hg with $3 drugs or use of $4 drugs regardless of level. There were
1115 deaths (305 total cardiovascular deaths) and 274 incident nonfatal or fatal strokes or coronary events.
Compared to the reference group (controlled hypertension and no CKD), participants without CKD and
with uncontrolled hypertension or aTRH had adjusted hazard ratios for all-cause mortality of 0.86
(0.741.01) and 1.09 (0.821.46), and those with CKD and controlled or uncontrolled hypertension, or
aTRH, of 1.33 (1.061.68), 1.14 (0.931.39), and 1.34 (0.981.85), respectively. Participants with aTRH and
CKD had a risk of coronary death more than 3 times higher than that of the reference group; participants
with aTHR, with or without CKD, had a risk of stroke more than twice as high, and those with CKD but
controlled hypertension a 2 times higher risk for cardiovascular deaths from other causes.
Discussion: CKD does not appear to amplify the risk of stroke and coronary events associated with aTRH in
this older population. The reasons for excess cardiovascular mortality from other causes associated with
controlled hypertension require further study.
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substantial numberwhohave treatment-resistant hyper-
tension.1–5 Apparent treatment-resistant hypertension
(aTRH), deﬁned as uncontrolled blood pressure
(BP), that is, $140/90 mm Hg while treated with 3
different antihypertensive drug classes or using 4 or
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International Reports (2016) -, -–-hypertension.5–9 Uncontrolled hypertension and aTRH
have been associated with higher risks of all-cause mor-
tality and major cardiovascular events in both the
general population10–12 and in CKD cohorts.9,13,14 The
optimal level of BP control, however, is still debated,
particularly for the older population and for individuals
with CKD. Target recommendations have recently risen
from <130/80 mm 0/80 to <140/90 for CKD patients
and up to <150/90 in the older population.15,16
A recent meta-analysis of randomized clinical trials
showed clear effects of intensive treatment to lower BP
on combined major cardiovascular events, but less
consistent ﬁndings for all-cause mortality and heart
failure.17 The recent Systolic Blood Pressure Interven-
tion Trial (SPRINT), however, reported a signiﬁcant1
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27% reduction in all-cause mortality, with intensive
versus standard BP control (systolic BP of <120
vs. <140 mm Hg) in adults with hypertension but
without diabetes.18 Notably, the beneﬁcial role of such
strict BP control was seen in middle-aged to elderly
people, including those 75 years and older. Neither the
meta-analysis nor SPRINT, however, demonstrated that
intensive BP control signiﬁcantly affects outcomes in
patients with CKD, although there was a 27% risk
reduction for mortality of borderline signiﬁcance in
SPRINT. These results are consistent with observa-
tional studies showing no advantage and even higher
mortality risk associated with achieving BP control
of <130/90 mm Hg in CKD patients,19–21 particularly
those on dialysis,19,22,23 and in community-dwelling
frail elderly people treated with multiple antihyper-
tensive agents.24 These observations may call into
question the recommendation for strict BP control in
elderly individuals with CKD. Nevertheless, insufﬁ-
cient data are available about whether CKD modiﬁes the
prognosis of uncontrolled and treatment-resistant
hypertension in this population.
To test our hypothesis that CKD might modify the
relation between hypertension control and outcomes
in older populations, we studied the interaction
between CKD and uncontrolled hypertension or aTRH
in their relations to all-cause mortality and major
cardiovascular events among hypertension-treated
elderly participants in the population-based Three-
City Study.
MATERIALS AND METHODS
Study Design and Participants
The Three-City Study is a population-based prospec-
tive cohort that included 9294 noninstitutionalized
individuals aged 65 years or older who were randomly
selected from electoral rolls of 3 French cities from
March 1999 through March 2001: Bordeaux (2104),
Dijon (4931), and Montpellier (2259). Details of the
study protocol have been published elsewhere.25 Both
BP and kidney function were measured at baseline in
8689 participants, 4262 of whom were then being
treated for arterial hypertension (Figure 1).
The institutional review committee of Kremlin-
Bicêtre University Hospital approved the study proto-
col, and all participants provided written informed
consent.
Assessment of Hypertension Control
Blood pressure was measured twice (5 minutes sepa-
rated the 2 measurements), most often at the partici-
pant’s home (61%), after at least 5 minutes at rest in a
seated position by trained nurses using a validated2digital electronic sphygmomanometer with an appro-
priately sized cuff on the right arm (OMRON M4;
OMRON Corp., Kyoto, Japan).26 The mean of these 2 BP
measurements was used in the analyses.
Hypertension was deﬁned as controlled if the
mean systolic and diastolic BP were <140 mm Hg
and <90 mm Hg, respectively, for participants taking
1 to 3 antihypertensive drug classes (cHT), and as
uncontrolled, but nonresistant, if it was $140 mm Hg
and/or $90 mm Hg with 2 drugs (ucHT); apparent
treatment-resistant hypertension (aTRH) was deﬁned
as BP of $140 mm Hg and/or $90 mm Hg in partic-
ipants receiving $3 antihypertensive drug classes or
$ 4, regardless of BP level.27,28 In sensitivity analyses,
we deﬁned aTRH including the use of diuretics as a
criterion as follows: BP of $140/90 mm Hg in partic-
ipants receiving $3 antihypertensive drug classes,
1 of them a diuretic, or $4, regardless of BP level;
consequently, the deﬁnition for uncontrolled hyper-
tension changed for BP of $140/90 mm Hg with
2 drugs or with 3 drugs excluding a diuretic,
whereas that for controlled hypertension remained
unchanged.27
Study Outcomes
We studied both all-cause and cardiovascular mortal-
ity, overall and by cause: stroke, coronary heart dis-
ease, other cardiovascular causes (including heart
failure, strict sudden death, myocardiopathy, unlocal-
ized aneurysm, and other cardiovascular deaths) as well
as incident fatal and nonfatal stroke and coronary
events. In addition, we investigated risk for recurrent
strokes and coronary events among participants with a
history of these diseases at baseline. All participants
were actively followed up to assess 10-year mortality,
and only 9 individuals were lost to follow-up. An
adjudication committee analyzed and conﬁrmed the
causes of death based on all available clinical infor-
mation collected from hospitalization reports and in-
terviews with the participant’s family physician or
specialists, nursing home staff (for participants who
entered in nursing home during follow-up), or proxy.29
Detailed deﬁnitions of the study endpoints have been
published elsewhere.25 Two adjudication committees,
one for coronary events and another for strokes, vali-
dated coding of myocardial infarction, sudden death,
and stroke and classiﬁed each event according to the
International Classiﬁcation of Diseases—10th Edition
(ICD-10).25 Coronary events included deﬁnite hospi-
talized angina, deﬁnite myocardial infarction, deﬁnite
cardiovascular death, coronary balloon dilatation, and
coronary artery bypass. Stroke was considered when a
new focal neurological deﬁcit of sudden or rapid onset
was diagnosed and attributable to a cerebrovascularKidney International Reports (2016) -, -–-
Figure 1. Flowchart of the study participants. BP, blood pressure; CHD, coronary heart disease.
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participant had multiple cardiovascular events during
follow-up, the date of the ﬁrst event was used in the
statistical analyses.25
Assessment of Chronic Kidney Disease
Serum creatinine was measured in a single labora-
tory with the Jaffé assay and further standardizedKidney International Reports (2016) -, -–-to the isotope dilution mass spectrometry (IDMS)
traceable enzymatic creatinine assay, as described
elsewhere.30 We calculated the estimated glomerular
ﬁltration rate (eGFR) using the Modiﬁcation of
Diet in Renal Disease (MDRD) equation without
correcting for race, which was unavailable.30 CKD
was deﬁned as an eGFR of <60 ml/min per
1.73 m2.313
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Trained staff administered standardized questionnaires
and performed clinical examinations at baseline. Soci-
odemographic data, smoking status, and history of
cardiovascular diseases (CVD) (coronary heart disease,
myocardial infarction, heart failure, stroke, peripheral
artery disease, artery surgery, or angioplasty) were
recorded. Body mass index (BMI) was calculated and
categorized (<25, 2530, $30 kg/m2). We used the
World Health Organization’s Anatomical Therapeutic
chemical classiﬁcation system to code drugs. All three
centers collected blood at baseline. Hypercholesterole-
mia was deﬁned as use of statins or fasting serum
cholesterol of $6.2 mmol/l. Diabetes was deﬁned as
the current use of antidiabetic drugs and/or fasting
serum glucose of $7.2 mmol/l, or nonfasting serum
glucose of $11 mmol/l.
Statistical Analyses
We classiﬁed participants into 6 groups combining 2
categories of CKD status based on eGFR < or 60 ml/min
per 1.73 m2 and the following 3 categories of hyper-
tension control status: controlled hypertension, un-
controlled hypertension, and aTRH. Participants with
controlled hypertension and no CKD formed the
reference group for the other 5 groups.
We ﬁrst compared participants’ baseline character-
istics among the 6 groups as deﬁned above, with a
nonparametric Wilcoxon test, analysis of variance, or a
c2 test, as appropriate. Second, we estimated crude
rates of all-cause and cardiovascular mortality, as well
as of fatal or nonfatal stroke and coronary heart disease,
and other cardiovascular deaths for each group
(Figure 1). Follow-up of participants for all outcomes
started from the date of interview with BP measure-
ments, which took place between 1999 and 2001, and
then participants were examined 5 times over a 10-year
period. Participants who did not develop the events of
interest at the time point in 2009 to 2010 were censored
at this date. For all-cause mortality, participants lost to
follow-up (n ¼ 9) were censored at their last follow-up
date. As we used a cause-speciﬁc Cox regression model,
participants who did not develop the outcomes of
interest (e.g., stroke or coronary heart disease, or car-
diovascular death other than stroke and coronary heart
disease) at the time point in 2009 to 2010 were also
censored at this time for the study of these outcomes.
Those who had no follow-up date for stroke or coro-
nary heart disease were considered lost to follow-up for
this event. The administrative censoring date was the
date of ﬁrst event or the date of last visit for that event,
or 2009 to 2010 time point. We estimated the hazard
ratios (HRs) and 95% conﬁdence intervals (95% CIs) of
mortality and cardiovascular outcomes associated with4exposure (combined hypertension control status and
CKD). In all models, we adjusted for established car-
diovascular risk factors including sex, diabetes, body
mass index, history of cardiovascular disease, smoking
status, hypercholesterolemia, and education level.
Third, we estimated incidence rates and adjusted HRs
(95% CIs) for fatal or nonfatal stroke or coronary heart
diseases associated with hypertension control status
and CKD in 3223 participants without a history of
either of these diseases at baseline (Figure 1). Similarly,
we estimated crude incidence rates (using a person-
years method) and adjusted HRs (95% CIs) for ﬁrst
occurrence of nonfatal or fatal stroke and coronary
heart diseases separately in 3858 and 3393 participants
without a previous stroke or coronary heart disease,
respectively. Finally, we estimated incidence rates and
adjusted HRs (95% CIs) for recurrent stroke or coro-
nary heart disease, together and separately, in 898
participants with a history of either stroke or coronary
heart disease (Figure 1). All HRs were adjusted for sex,
diabetes, body mass index, smoking status, hyper-
cholesterolemia, and education level.
In all Cox proportional hazards regression models,
we used age at baseline as a time-scale to better control
for the confounding effect of age on studied outcomes
in this longitudinal study comprising elderly partici-
pants.32,33 We formally tested the interaction between
CKD and hypertension control status in their relations
with all studied outcomes by using Cox models
including hypertension control status and CKD sepa-
rately, as well as an interaction term. Similarly, we also
tested interactions between the variable of interest
(combined CKD and hypertension control status) and
diabetes, sex, history of CVD, and body mass index
(BMI) in relation to the outcomes studied. The pro-
portional hazards assumption was tested for all models
using the Schoenfeld residuals method. All analyses
were conducted with SAS software 9.4 (SAS Institute,
Cary, NC); all probabilities were 2-tailed, and a P value
of #0.05 was considered as statistically signiﬁcant.
RESULTS
Participant Characteristics
At baseline, the mean age of the 4262 study partici-
pants treated for hypertension was 75.1  5.6 years;
40% were men and 60% were women. Overall, 31.2%
had controlled hypertension, 62.3% uncontrolled
hypertension, and 6.5% aTRH; 19.1% had CKD. In
those with CKD, 57.0% had uncontrolled hypertension
and 11.8% aTRH, compared to 63.6% and 5.2%,
respectively, of those without CKD. Participants with
CKD or uncontrolled hypertension or aTRH were on
average older, more often men, current or former
smokers, or obese, and more often had diabetes,Kidney International Reports (2016) -, -–-
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counterparts with controlled hypertension and no CKD
(Table 1). The maximum follow-up was 10 years irre-
spective of the outcome of interest. Median systolic and
diastolic BPs were of the same order of magnitude in
participants with and without CKD for those with
controlled or uncontrolled hypertension, but systolic
BP was higher in participants with aTRH and CKD. The
percentage of participants on more than 4 antihyper-
tensive drug classes was twice as high in those with
compared to those without CKD.
All-Cause and Cardiovascular Mortality
According to CKD and Hypertension Control
Status
Over a median (interquartile range) follow-up of 8.8
(7.69.4) years, 9 participants were lost to follow-up for
mortality, and 1115 deaths were reported, 305 of them
from cardiovascular causes: 38 from stroke, 79 from
coronary heart disease, and 188 from other cardiovas-
cular causes. Compared with the reference group with
controlled hypertension and no CKD, participants with
uncontrolled hypertension or aTRH and no CKD did not
have a higher risk of all-cause or cardiovascular mor-
tality after multivariable adjustment (Table 2). In par-
ticipants with CKD, controlled hypertension wasTable 1. Participant baseline characteristics according to CKD and hype
Baseline characteristic
Without CKD (n [ 3450)
cHT ucHT aTRH
n [ 1077 n [ 2194 n [ 179
Age, yrc 74.4  5.3 74.6  5.4 75.1  5.6
Men 31.8 43.6 46.9
Low education level 20.7 20.8 24.6
Current or former smoker 34.3 40.2 43.6
BMI $30 kg/m2 17.2 17.5 29.1
Hypercholesterolemia 57.4 57.2 56.4
Diabetesb 11.0 14.3 31.3
History of CVD 13.2 10.5 24.6
eGFR, ml/min/1.73m2c 79.4  13.2 79.0  12.7 79.8  14.6
Blood pressure, mm Hg
SBP, median (IQR) 129 (121–135) 157 (148–170) 159 (149–17
DBP, median (IQR) 75 (69–80) 87 (80–94) 86 (80–93)
No. of drugs, median (IQR)d 5 (4–7) 5 (3–7) 7 (6–9)
Antihypertensive drugs
1 class 66.5 68.5
2 classes 28.1 31.5
3 classes 5.4 89.9
$4 classes 9.1
All values are percentages if not indicated otherwise.
aTRH, apparent treatment-resistant hypertension (deﬁned as systolic and diastolic blood pre
drugs$4); BMI, body mass index; CKD, chronic kidney disease (deﬁned as estimated glomerula
diastolic blood pressure <140/90 mm Hg while taking 13 antihypertensive drugs); CVD, cardiov
calculated with the Modification of Diet for Renal Diseases equation; IQR, interquartile range;
diastolic blood pressure $140/90 while taking 1 or 2 antihypertensive drugs).
aP value for global comparison of baseline characteristics of participants according to hypert
bDiabetes defined as use of antidiabetic medication or fasting glycemia $7.2 mmol/l or nonfa
cValues are mean  SD.
dNo. of drugs refers to total number of drug classes.
Kidney International Reports (2016) -, -–-associated with a signiﬁcantly higher risk of all-cause
and cardiovascular mortality than in the reference
group, mainly from causes other than stroke and coro-
nary heart disease (73% from heart failure), whereas
aTRH was associated with a signiﬁcantly higher risk
of mortality from coronary heart disease (Table 2). Un-
controlled hypertension in participants with CKD was
not associatedwith highermortality than in the reference
group. Because of the small number of stroke deaths (7
among the 812 participants with CKD, and only 1 among
the 96 with aTRH), we were unable to estimate HRs for
this outcome. Interactions between CKD and hyperten-
sion control status in relation to all-cause or stroke and
coronary heart disease mortality were not statistically
signiﬁcant, but the interaction with the relation to car-
diovascular mortality from other causes did approach
statistical signiﬁcance (P for interaction ¼ 0.07). No sig-
niﬁcant interactionwas foundwith sex, BMI, diabetes, or
history of CVD in the relations that we studied. The in-
clusion of diuretic use as a criterion in the deﬁnition of
aTRH yielded similar results (Supplementary Table S1).
Incident Stroke and Coronary Events According
to CKD and Hypertension Control Status
For combined nonfatal and fatal strokes or coronary
heart disease, the median follow-up (interquartilertension control status
With CKD (n [ 812)
P valuea
cHT ucHT aTRH
n [ 253 n [ 463 n [ 96
76.9  5.8 77.7  5.8 77.9  6.1 <0.001
32.8 37.4 44.8 <0.001
17.8 24.6 16.7 0.170
37.9 37.8 43.8 0.016
17.4 17.1 27.1 <0.001
67.6 58.3 62.5 0.047
9.5 10.8 29.2 <0.001
18.2 12.1 32.3 <0.001
50.3  8.2 50.8  7.9 48.1  8.7 <0.001
5) 130 (122–135) 157 (148–172) 167 (151–179)
73 (67–80) 86 (79–93) 85 (79–91)
6 (4–8) 5 (4–7) 7 (6–9)
50.2 57.0
37.9 42.9
11.8 79.2
20.8
ssure $140/90 while taking $3 antihypertensive drugs or number of antihypertensive
r ﬁltration rate <60 ml/min/1.73 m2); cHT, controlled hypertension (defined as systolic and
ascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate
SPB, systolic blood pressure; ucHT, uncontrolled hypertension (defined as systolic and
ension control and CKD status.
sting glycemia $11 mmol/l.
5
Table 2. Crude mortality rates and adjusted hazard ratios for all-cause and cardiovascular deaths according to CKD and hypertension control
status
Mortality n Person-years Events
Crude IR [95% CI]
per 1000 person-years
Adjusted HR
[95% CI]a P for interactionb
All-cause 0.95
All participants 4262 33,904 1115 32.9 [31.0–34.9]
Without CKD
cHT (Ref) 1077 8778 260 29.6 [26.2–33.4] 1
ucHT 2194 17,758 480 27.0 [24.7–29.5] 0.86 [0.74–1.01]
aTRH 179 1368 59 43.1 [33.1–55.2] 1.09 [0.82–1.46]
With CKD
cHT 253 1867 100 53.5 [43.8–64.8] 1.33 [1.06–1.68]
ucHT 463 3476 170 48.9 [42.0–56.7] 1.14 [0.93–1.39]
aTRH 96 656 46 70.1 [51.9–92.6] 1.34 [0.98–1.85]
All cardiovascularc 0.68
All participants 4262 33,904 305 9.0 [8.0–10.0]
Without CKD
cHT (Ref) 1077 8778 68 7.7 [6.1–9.8] 1
ucHT 2194 17,758 119 6.7 [5.6–8.0] 0.82 [0.60–1.11]
aTRH 179 1368 21 15.4 [9.8–23] 1.34 [0.81–2.23]
With CKD
cHT 253 1867 33 17.7 [12.4–24.5] 1.63 [1.07–2.48]
ucHT 463 3476 49 14.1 [10.6–18.5] 1.28 [0.87–1.87]
aTRH 96 656 15 22.8 [13.3–36.7] 1.56 [0.88–2.77]
Coronary heart disease 0.21
All participants 4262 33,904 79 2.3 [1.9–2.9]
Without CKD
cHT (Ref) 1077 8778 15 1.7 [1.0–2.7] 1
ucHT 2194 17,758 36 2.0 [1.4–2.8] 1.01 [0.54–1.88]
aTRH 179 1368 3 2.2 [0.6–5.9] 0.71 [0.2–2.53]
With CKD
cHT 253 1867 5 2.7 [1.0–5.9] 1.10 [0.40–3.07]
ucHT 463 3476 12 3.5 [1.9–5.8] 1.36 [0.62–2.99]
aTRH 96 656 8 12.2 [5.7–23.0] 3.27 [1.34–7.99]
Cardiovascular death other than stroke or
coronary heart diseased
0.07
All participants 4262 33,904 188 5.5 [4.8–6.4]
Without CKD
cHT (Ref) 1077 8778 44 5.0 [3.7–6.7] 1
ucHT 2194 17,758 63 3.5 [2.8–4.5] 0.70 [0.47–1.04]
aTRH 179 1368 16 11.7 [7.0–18.5] 1.69 [0.93–3.08]
With CKD
cHT 253 1867 26 13.9 [9.3–20.1] 1.94 [1.18–3.18]
ucHT 463 3476 33 9.5 [6.7–13.2] 1.37 [0.86–2.19]
aTRH 96 656 6 9.1 [3.8–18.8] 1.02 [0.43–2.42]
aTRH, apparent treatment-resistant hypertension (systolic and/or diastolic blood pressure $140 and/or $90 while taking $3 antihypertensive drugs or number of antihypertensive
drugs $4); CHD, coronary heart diseases; cHT, controlled hypertension; CKD, chronic kidney disease (deﬁned as estimated glomerular ﬁltration rate <60 ml/min/1.73m2; cHT: systolic
and diastolic blood pressure <140/90 mm Hg while taking 13 antihypertensive drugs); HR, hazard ratio; IR, incidence rate; ucHT, uncontrolled hypertension (defined as systolic and/or
diastolic blood pressure $140 and/or $90 while taking 1 or 2 antihypertensive drugs).
aAll models were adjusted for center, sex, diabetes (defined as use of antidiabetic medication or fasting glycemia $7.2 mmol/L or nonfasting glycemia $11 mmol/l), history of car-
diovascular events, body mass index, hypercholesterolemia, smoking status, and education level.
bAll interaction between hypertension control status and chronic kidney disease.
cAll cardiovascular mortality included deaths from stroke, coronary heart disease, strict sudden death, heart failure, and other cardiovascular deaths.
dCardiovascular deaths other than stroke or coronary heart disease included heart failure, strict sudden death, myocardiopathy, unlocalized aneurysm, and other cardiovascular deaths.
CLINICAL RESEARCH J Kaboré et al.: Hypertension Control, Outcomes in Older People With CKDrange) was 8.4 (5.49.2) years, 8.5 (5.6–9.2) for nonfatal
and fatal strokes, and 8.4 (5.5–9.2) for nonfatal and fatal
coronary heart diseases. A total of 169 participants had
no follow-up date for nonfatal and fatal stroke, 155 for
nonfatal and fatal coronary heart disease, and 141 for
both. Because of the exclusion of prevalent cases at
baseline, the number of participants lost to follow-up
for these events varies. During follow-up, 1786incident fatal or nonfatal strokes and 225 coronary
events were reported; 349 participants had 1 or both
events. Cause-speciﬁc Cox regression models showed
that, compared with the reference group, participants
with uncontrolled hypertension and no CKD had a 50%
higher risk of stroke, and those with aTRH had a risk
more than 2 times higher, whether or not they had CKD
(Table 3). There was no signiﬁcant interaction withKidney International Reports (2016) -, -–-
Table 3. Crude incidence rates and adjusted hazard ratios for ﬁrst fatal and nonfatal stroke or coronary heart disease according to CKD and
hypertension control status
Baseline characteristic n Person-years Events
Crude IR [95% CI]
per 1000 person-years Adjusted HR [95% CI]a P for interactionb
Stroke or coronary heart diseasec 0.74
All participants 3223 23,245 349 15 [13.5–16.7]
Without CKD
cHT 786 5872 75 12.8 [10.1–15.9] 1
ucHT 1745 12,650 194 15.3 [13.3–17.6] 1.01 [0.77–1.32]
aTRH 113 762 20 26.2 [16.5–39.7] 1.50 [0.90–2.47]
With CKD
cHT 168 1184 15 12.7 [7.4–20.4] 0.91 [0.52–1.59]
ucHT 356 2405 38 15.8 [11.4–21.4] 0.95 [0.64–1.42]
aTRH 55 370 7 18.9 [8.4–37.1] 0.98 [0.45–2.15]
Stroke 0.87
All participants 3858 28,284 178 6.3 [5.4–7.3]
Without CKD
cHT 970 7354 31 4.2 [2.9–5.9] 1
ucHT 2034 15,071 103 6.8 [5.6–8.3] 1.51 [1.00–2.28]
aTRH 157 1088 12 11.0 [6–18.7] 2.33 [1.18–4.61]
With CKD
cHT 219 1535 8 5.2 [2.5–9.8] 1.08 [0.49–2.35]
ucHT 404 2750 18 6.5 [4.0–10.1] 1.27 [0.70–2.29]
aTRH 74 485 6 12.4 [5.1–25.5] 2.12 [0.87–5.17]
Coronary heart disease 0.68
All participants 3393 24,588 225 9.2 [8.0–10.4]
Without CKD
cHT 829 6305 50 8.1 [6.0–10.5] 1
ucHT 1821 13,449 121 9.1 [7.6–10.8] 0.92 [0.65–1.28]
aTRH 124 861 12 14.0 [7.7–23.8] 1.14 [0.59–2.17]
With CKD
cHT 175 1263 10 8.0 [4.1–14.2] 0.94 [0.47–1.86]
ucHT 380 2625 24 9.3 [6.1–13.6] 0.89 [0.54–1.47]
aTRH 64 403 8 19.9 [9.4–37.5] 1.69 [0.79–3.62]
aTRH, apparent treatment-resistant hypertension (deﬁned as systolic and/or diastolic blood pressure $140 and/or $90 while taking $3 antihypertensive drugs or number of antihy-
pertensive drugs $4); cHT, controlled hypertension (deﬁned as systolic and diastolic blood pressure <140/90 mm Hg while taking 13 antihypertensive drugs); CKD, chronic kidney
disease (deﬁned as estimated glomerular ﬁltration rate < 60 mL/min/1.73m2); HR, hazard ratio; IR, incidence rate; ucHT, uncontrolled hypertension (defined as systolic and/or diastolic
blood pressure $140 and/or $90 while taking 1 or 2 antihypertensive drugs).
aAll models were adjusted for center, sex, diabetes, history of cardiovascular events, body mass index, hypercholesterolemia, smoking status and education level.
bAll interaction between hypertension control status and chronic kidney disease.
cCombined incident fatal and nonfatal stroke or coronary heart disease: defined as the first occurrence of stroke or coronary heart disease, whichever occurred first. (Participants with
history of stroke and/or coronary heart disease, stroke, or coronary heart disease were excluded when estimating the risk for combined fatal and nonfatal incident stroke or coronary
heart disease, incident stroke, and incident coronary heart disease respectively).
J Kaboré et al.: Hypertension Control, Outcomes in Older People With CKD CLINICAL RESEARCHCKD in the association between hypertension control
status and risk of stroke. Neither aTRH nor uncon-
trolled hypertension was signiﬁcantly associated with a
higher risk of coronary events, with or without CKD.
In the sensitivity analysis, the use of the diuretic drug
criterion in the deﬁnition of aTRH tended to weaken
the HR estimates for stroke (Supplementary Table S2).
Recurrent Stroke and Coronary Events
According to CKD and Hypertension Control
Status
For combined recurrent strokes or coronary heart dis-
eases, the median follow-up (interquartile range) was 6.4
(3.5–8.8) years, 6.1 (3.5–8.6) for recurrent strokes, and6.8
(3.6–8.9) for recurrent coronary heart diseases. Partici-
pants with CKD and uncontrolled hypertension or aTRH
had a risk of combined recurrent stroke or coronary
event (i.e., any second stroke or coronary event) thatKidney International Reports (2016) -, -–-was approximately twice as high as that in the reference
group, mostly due to coronary heart disease, whereas
their counterparts without CKD had no such excess risk
(Table 4). The interaction between CKD and hyperten-
sion control status, however, was not statistically sig-
niﬁcant. As above, the sensitivity analysis tended to
weaken the HR estimates (Supplementary Table S3).
DISCUSSION
In this community-dwelling elderly population, par-
ticipants with CKD had an overall higher risk of all-
cause and cardiovascular mortality, regardless of their
hypertension control status. As expected, both aTRH
and uncontrolled hypertension were associated with
higher risks of incident stroke, apparently unmodiﬁed
by CKD; participants with both CKD and aTRH also
had signiﬁcantly higher risks of coronary death and of
combined recurrent stroke or coronary events. The7
Table 4. Crude incidence rates and adjusted hazard ratios for recurrent fatal or nonfatal stroke or coronary heart disease according to CKD and
hypertension control status
Baseline characteristics Number Person-years Events
Crude IR [95% CI]
(per 1000 person-years) Adjusted HR [95% CI]a P for interactionb
Stroke or coronary heart diseasec 0.10
All participants 898 5373 204 38.0 [33.0–43.5]
Without CKD
cHT 245 1554 50 32.2 [24.2–42.1] 1
ucHT 404 2492 94 37.7 [30.7–45.9] 1.08 [0.76–1.53]
aTRH 59 381 8 21.0 [9.9–39.6] 0.60 [0.28–1.29]
With CKD
cHT 66 352 13 36.9 [20.7–61.3] 1.10 [0.59–2.06]
ucHT 89 434 25 57.6 [38.2–83.6] 1.70 [1.04–2.80]
aTRH 35 159 14 87.8 [50.3–143.3] 2.15 [1.16–3.98]
Stroke
All participants 235 1381 32 23.2 [16.1–32.3]
Without CKD
cHT 59 377 6 15.9 [6.6–32.8] 1
ucHT 106 636 16 25.2 [15.0–39.9] Not estimated
aTRH 14 90 1 11.1 [1.0–51.8] Not estimated
With CKD
cHT 10 49 0 Not estimated Not estimated
ucHT 34 165 7 42.3 [18.9–83.1] Not estimated
aTRH 12 64 2 31.0 [6.2–99.4] Not estimated
Coronary heart disease 0.13
All participants 714 4379 143 32.7 [27.6–38.3]
Without CKD
cHT 198 1270 38 29.9 [21.5–40.6] 1
ucHT 322 2063 64 31 [24.1–39.3] 1.00 [0.66–1.52]
aTRH 48 310 4 12.9 [4.3–30.7] 0.40 [0.14–1.15]
With CKD
cHT 59 322 12 37.3 [20.4–63.1] 1.25 [0.64–2.43]
ucHT 61 299 16 53.4 [31.8–84.7] 1.98 [1.08–3.64]
aTRH 26 114 9 78.5 [38.8–143.2] 2.04 [0.95–4.37]
aTRH, apparent treatment-resistant hypertension (deﬁned as systolic and/or diastolic blood pressure $140 and/or $90 while taking $3 antihypertensive drugs or number of antihy-
pertensive drugs $4); cHT, controlled hypertension (deﬁned as systolic and diastolic blood pressure <140/90 mm Hg while taking 13 antihypertensive drugs); CKD, chronic kidney
disease (deﬁned as estimated glomerular ﬁltration rate <60 mL/min/1.73m2); HR, hazard ratio; IR, incidence rate; ucHT, uncontrolled hypertension (systolic and/or diastolic blood
pressure $140 and /or $90 while taking 1 or 2 antihypertensive drugs).
aAll models were adjusted for center, sex, diabetes, body mass index, hypercholesterolemia, smoking status, and education level.
bAll interactions between hypertension control status and chronic kidney disease.
cCombined fatal and nonfatal stroke and CHD: defined as the recurrence of either a stroke or CHD.
CLINICAL RESEARCH J Kaboré et al.: Hypertension Control, Outcomes in Older People With CKDmost intriguing ﬁnding was the excess cardiovascular
mortality risk from other causes, mainly heart failure,
observed in participants with CKD and well-controlled
hypertension.
The ﬁndings of our study are difﬁcult to compare
with those of others, which have usually included
younger participants, have not systematically assessed
CKD as a potential effect modiﬁer in the relation of aTRH
with outcomes, and have sometimes used BP values
of $130/80 mm Hg rather than $140/90 to deﬁne poor
BP control in individuals with CKD. It was nevertheless
somewhat surprising to ﬁnd that aTRH in these elderly
participants was not signiﬁcantly associated with a
higher risk of all-cause mortality. This ﬁnding differs
from some,10,11,34 although not all,12,35 non-CKD cohort
studies that have compared all-cause mortality between
individuals with and without aTRH after adjusting for
CKD. In the Antihypertensive and Lipid-Lowering
treatment to prevent Heart Attack Trial (ALLHAT),8aTRHdid not signiﬁcantly increase all-causemortality in
participants older than 65 years.34 The somewhat higher
HR for all-cause mortality associated with aTRH in our
study in participants with CKD compared with the
reference group (with controlled hypertension and no
CKD) is probably due to the well-established higher risk
conferred by CKD,36 whichwe have previously reported
for this population,30 rather than to aTRH. Among par-
ticipants with CKD, those with aTRH were not at
higher risk than those with controlled hypertension, in
contrast to ﬁndings from 2 other CKD cohorts.9,13
Our ﬁndings regarding cardiovascular risk are
consistent with previous studies for several points but
differ for others. First, we observed a risk of mortality
from coronary heart disease associated with aTRH in
participants with CKD, but not in those without CKD,
and no signiﬁcantly higher rate of coronary heart
disease events. Several studies have shown higher rates
of coronary heart disease events associated withKidney International Reports (2016) -, -–-
J Kaboré et al.: Hypertension Control, Outcomes in Older People With CKD CLINICAL RESEARCHaTRH, both before and after adjustment for CKD.11,12,37
Discrepancies in ﬁndings about coronary heart disease
events between these studies and ours may be due to
a lack of power in our study. It may also result, how-
ever, from the impact of CKD per se on mortality rather
than on the incidence of coronary heart disease in
relation to aTRH. Support for this hypothesis comes
from repeated ﬁndings that the concomitant presence
of CKD increases mortality risk in a variety of chronic
diseases.38,39
Second, participants with aTRH had a risk of inci-
dent stroke that was more than twice as high as that in
the reference group, with HRs of similar magnitude
with or without CKD. This was true for either aTRH
deﬁnition that we used, although study power was
stronger without diuretic use as a criterion. Partici-
pants with uncontrolled hypertension were also at
higher risk for stroke, although the association was
statistically signiﬁcant only in those without CKD.
These ﬁndings conﬁrm the well-established role of
hypertension in the occurrence of stroke.12,34,35 In
addition, we showed that CKD appears to inﬂuence the
recurrence of stroke and coronary heart disease.
One of the most striking observations of our study is
that participants with CKD and controlled hypertension
were at signiﬁcantly higher risk for cardiovascular
mortality from other causes than those with controlled
hypertension without CKD. In ALLHAT, patients with
aTRH were at higher risk for fatal, hospitalized, or
treated nonhospitalized heart failure.34 Although
unexpected, this ﬁnding is in line with some studies
showing an adverse effect of excessive BP reduction,24
demonstrated by the J-shaped association between BP
and mortality risk in patients with CKD, whether or not
they were on dialysis.20,40,41 In apparent contrast,
SPRINT, which compared the effect of tight systolic BP
control to a level of <120 mm Hg versus standard BP
control (<140 mm Hg) in hypertensive patients over a
median follow-up of 3.3-years, showed signiﬁcant risk
reductions for cardiovascular outcomes and all-cause
mortality, even in the subgroup of patients older than
75 years.18 It also showed a signiﬁcant reduction in the
risk of heart failure. Nonetheless, this trial did not
include patients with difﬁcult-to-control hypertension,
and there were important adverse events in the inter-
vention arm, especially severe hypotension, syncope,
and acute kidney injury, which do not preclude a worse
long-term prognosis for these patients.42 Moreover,
SPRINT failed to demonstrate that intensive treatment
that lowered BP to its target ranges had any effect on
outcomes in patients with CKD. In our study, heart
failure was classiﬁed as the primary cause of death for
three-fourths of the participants who died of other
cardiovascular diseases. It is possible that a lower BPKidney International Reports (2016) -, -–-level at baseline reﬂects the heart’s compromised ca-
pacity to maintain an adequate ejection fraction
and thus makes it easier to achieve BP control. The
frequency of heart failure due to nonischemic heart
disease increases as CKD progresses. Coronary athero-
sclerosis is the most common cause of death in the
general population, but not among patients with CKD.
In this population, decreased cardiac perfusion of
various causes and diffuse interstitial myocardial
ﬁbrosis with increased oxygen diffusion distance are
the major causes of congestive heart failure, arrhythmia,
and sudden cardiac death.43,44 Moreover, other factors
such as concomitant diabetes, electrolyte shifts, diva-
lent ion abnormalities, sympathetic overactivity,
impaired baroreﬂex effectiveness, inﬂammation, infec-
tion, and inappropriate drug use also contribute to the
higher risk of mortality in patients with CKD.43–46
Thus, we cannot exclude the possibility that partici-
pants with CKD and controlled hypertension at baseline
had low BP due to incipient heart failure.
Major strengths of this study include its large sam-
ple size and the low number of participants lost to
follow-up for mortality. In addition, standardized BP
was measured by trained nurses during in-home
examination in the majority of participants, which
lessens the risk of white-coat hypertension. Home BP
monitoring has been shown to be superior to ofﬁce BP
in predicting target organ damage and all-cause mor-
tality47 and functional decline in elderly individuals.48
Moreover, creatinine measurements were taken in a
single laboratory with further calibration to the IDMS
reference method, and long-term follow-up and adju-
dication of cardiovascular events. Of note, we used the
MDRD equation with which eGFR was normally
distributed, in contrast to the CKD-EPI equation in this
elderly population. Previous analyses showed that both
equations provided similar prevalence estimates of
CKD8 and similar hazard ratios of all-cause and car-
diovascular mortality associated with CKD.30
Our study also has limitations. First, we included
only elderly participants, precluding extrapolation to
other age groups. Second, as treatment adherence and
ambulatory BP data were not available, true treatment-
resistant hypertension may have been misclassiﬁed
with pseudo-resistance in a number of cases. Third,
albuminuria was not available at baseline and therefore
could not be adjusted for in the multivariable analyses
or used in the deﬁnition of CKD. Fourth, we may have
lacked statistical power in some of the associations
studied, particularly for stroke events. There was also a
signiﬁcant loss to follow-up for stroke and coronary
events, with the ensuing potential selection bias.
Finally, the observational design of the study makes
causal interpretation impossible.9
CLINICAL RESEARCH J Kaboré et al.: Hypertension Control, Outcomes in Older People With CKDIn conclusion, we found that community-dwelling
elderly individuals with both CKD and aTRH were at
higher risk for coronary heart disease mortality and
incident stroke. In this study, the presence of CKD did
not appear to amplify the risks for the occurrence of
these 2 disease entities associated with aTRH (P value
for interaction not statistically signiﬁcant), but we
cannot rule out that it may enhance the lethality of
coronary heart disease (P for interaction ¼ 0.07). Using
either deﬁnition of aTRH, with or without the diuretic
use criteria, did not alter the main conclusion of this
study. Adequate monitoring of kidney function and
appropriate titration of antihypertensive medication
with decreasing GFR may help to decrease aTRH and
thereby impede its harmful prognosis. The reasons that
older people with CKD and controlled hypertension
might be at higher risk for CV mortality from heart
failure require further study. Randomized controlled
studies are needed to assess whether or not strict BP
control, compared to less strict control, is beneﬁcial in
elderly people, and whether or not mild-to-moderate
CKD is an additional aggravating condition.
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